Nonsurgical treatment of uterine fibroids

Infertility and Reproductive Medicine Clinics of North America

Volumn 13, Issue 2, 2002, Pages 393-405

  Stewart, Elizabeth A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; GONADORELIN AGONIST; PROGESTERONE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; STEROID HORMONE;

FEMALE; HORMONE BLOOD LEVEL; HUMAN; LASER SURGERY; LEIOMYOMA; PREGNANCY; REVIEW; ULTRASOUND THERAPY; UTERINE ARTERY EMBOLIZATION; UTERUS MYOMA;

EID: 0036263654     PISSN: 10479422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Variation in the incidence of uterine leiomyomata among premenopausal women by age and race
2. The frequency of uterine leiomyomas
3. A conservative approach to the management of uterine leiomyoma: Pituitary desensitization by a luteinizing hormone-releasing hormone analogue
4. Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri
5. Toward removing uterine fibroids without surgery: Subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase
6. Rapid reduction of uterine myomas after short-term treatment with microencapsulated D-Trp6-LHRH
7. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): A luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot
8. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist
9. Treatment of leiomyomata uteri with leuprolide acetate depot: A double-blind, placebo-controlled, multicenter study
10. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: Assessment by magnetic resonance imaging
11. Goserelin therapy before surgery for uterine fibroids
12. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin
13. Medical treatment of uterine fibroids
14. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist
15. Vaginal hemorrhage associated with degenerating submucous leiomyomata during leuprolide acetate treatment
16. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate
17. The place of Zoladex in deferred surgery for uterine fibroids
18. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: A randomized controlled trial
19. A prospective randomized study to evaluate leuprolide acetate treatment before laparoscopic myomectomy: Efficacy and ultrasonographic predictors
20. Surgical alternatives to hysterectomy in the management of leiomyomas
21. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: The estrogen threshold hypothesis
22. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri
23. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: A prospective, randomized, double blind, placebo-controlled, crossover trial
24. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: A pilot study
25. Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin): Lack of shrinkage of uterine fibroids
26. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: Comparison between two regimens of HRT
27. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata
28. Progesterone: A critical role in the pathogenesis of uterine myomas
29. Regression of uterine leiomyomata in response to the antiprogesterone RU 486
30. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma
31. Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata
32. Interferon-alpha is a potent inhibitor of basic fibroblast growth factor-stimulated cell proliferation in human uterine cells
33. Remarkable and persistent shrinkage of uterine leiomyoma associated with interferon alfa treatment for hepatitis
34. Arterial embolisation to treat uterine myomata
35. Preliminary experience with uterine artery embolization for uterine fibroids
36. Uterine arterial embolization for the management of leiomyomas: Quality-of-life assessment and clinical response
37. Uterine artery embolization for the treatment of uterine fibroids
38. Transcatheter uterine artery embolisation to treat large uterine fibroids
39. Embolization of uterine fibroids
40. Selective uterine artery embolization as primary treatment for symptomatic leiomyomata uteri
41. Uterine fibroid embolization: Measurement of health-related quality of life before and after therapy
42. Fibroid-related menorrhagia: Treatment with superselective embolization of the uterine arteries and midterm follow-up
43. Uterine artery embolization for leiomyomata
44. Patient radiation dose associated with uterine artery embolization
45. Transcervical expulsion of a fibroid as a result of uterine artery embolization for leiomyomata
46. Vaginal expulsion of submucosal fibroids after uterine artery embolization: A report of three cases
47. Symptomatic fibroleiomyomata: MR imaging of the uterus before and after uterine arterial embolization
48. Uterine fibroleiomyoma: MR imaging appearances before and after embolization of uterine arteries
49. Fatal septicaemia after fibroid embolisation
50. Fibroid embolisation: A technique not without significant complications
51. Pregnancy after embolization of uterine myoma: Report of 12 cases
52. Ovarian function after uterine artery embolization for leiomyomata: Assessment with use of serum follicle stimulating hormone assay
53. Magnetic-resonance-guided percutaneous laser ablation of uterine fibroids
54. Treatment of uterine fibroid tumors in a nude mouse model using high-intensity focused ultrasound